Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 14Terminated 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Nivolumab 7pembrolizumab 4Ipilimumab 4cemiplimab 3Specimen Handling 3relatlimab 2Watchful Waiting 2Standard of Care 2Prednisone 2Phototherapy 2Photochemotherapy 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Dermoscopy 2Cryotherapy 2Carboplatin 2vedolizumab 1trametinib 1toripalimab 1tirbanibulin 1sulforaphane 1gadopiclenol 1famitinib 1decitabine and cedazuridine drug combination 1daromun 1calcipotriene 1anlotinib 1X-Rays 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Everolimus × Dermatologic × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡